Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$34.74
-6.6%		$22.53
$9.15
▼
$41.14
$4.14B-0.213.92 million shs1.36 million shs
Celcuity, Inc. stock logo
CELC
Celcuity
$88.44
-5.1%		$94.64
$44.42
▼
$151.02
$4.56B0.2747,478 shs610,269 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$57.86
-4.4%		$54.62
$14.78
▼
$62.32
$4.43B0.271.06 million shs584,978 shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$3.93
-3.9%		$3.57
$2.61
▼
$6.55
$1.22B2.162.53 million shs2.14 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-6.56%-10.14%+76.08%+142.09%+267.62%
Celcuity, Inc. stock logo
CELC
Celcuity
-5.15%-5.44%+6.29%-33.44%+77.02%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-4.36%-3.28%+9.23%+46.22%+179.79%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-3.91%+0.51%+23.97%+19.09%+16.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$34.74
-6.6%		$22.53
$9.15
▼
$41.14
$4.14B-0.213.92 million shs1.36 million shs
Celcuity, Inc. stock logo
CELC
Celcuity
$88.44
-5.1%		$94.64
$44.42
▼
$151.02
$4.56B0.2747,478 shs610,269 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$57.86
-4.4%		$54.62
$14.78
▼
$62.32
$4.43B0.271.06 million shs584,978 shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$3.93
-3.9%		$3.57
$2.61
▼
$6.55
$1.22B2.162.53 million shs2.14 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-6.56%-10.14%+76.08%+142.09%+267.62%
Celcuity, Inc. stock logo
CELC
Celcuity
-5.15%-5.44%+6.29%-33.44%+77.02%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-4.36%-3.28%+9.23%+46.22%+179.79%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-3.91%+0.51%+23.97%+19.09%+16.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$36.505.07% Upside
Celcuity, Inc. stock logo
CELC
Celcuity
2.82
Moderate Buy$154.5574.75% Upside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.78
Moderate Buy$75.0029.62% Upside
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
2.80
Moderate Buy$9.33137.49% Upside

Current Analyst Ratings Breakdown

Latest SANA, CELC, ELVN, and AMLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$55.00 ➝ $57.00
8/24/2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$40.00 ➝ $55.00
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$28.00 ➝ $52.00
8/18/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$30.00 ➝ $42.00
8/18/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$34.00 ➝ $55.00
8/18/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/18/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$78.00
8/18/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$62.00 ➝ $73.00
8/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$165.00 ➝ $175.00
8/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M44.30N/AN/A$2.15 per share16.16
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A($0.26) per shareN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$12.22 per shareN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/A$0.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.43N/AN/AN/AN/A-52.92%-48.53%11/5/2026 (Estimated)
Celcuity, Inc. stock logo
CELC
Celcuity
-$177.04M-$4.30N/AN/AN/AN/A-350.78%-41.54%11/11/2026 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$103.69M-$1.67N/AN/AN/AN/A-18.55%-18.09%11/11/2026 (Estimated)
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$244.17M-$0.76N/AN/AN/AN/A-103.02%-39.16%11/5/2026 (Estimated)

Latest SANA, CELC, ELVN, and AMLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.16-$1.44-$0.28-$1.44$4.42 millionN/A
8/11/2026Q2 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.1469-$0.13+$0.0169-$0.22N/AN/A
8/6/2026Q2 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3609-$0.39-$0.0291-$0.39N/AN/A
8/5/2026Q2 2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.3872-$0.49-$0.1028-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
12.12
12.12
Celcuity, Inc. stock logo
CELC
Celcuity
6.04
8.93
8.93
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
64.07
64.07
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/A
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
88.23%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
Celcuity, Inc. stock logo
CELC
Celcuity
13.33%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
25.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
200111.42 million99.28 millionOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
4048.93 million42.41 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5073.27 million71.07 millionOptionable
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
380299.36 million223.32 millionOptionable

Recent News About These Companies

Canada Pension Plan Investment Board Purchases Shares of 10,218,400 Sana Biotechnology, Inc. $SANA
August 28 at 4:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-canada-pension-plan-investment-board-purchases-shares-of-10218400-sana-biotechnology-inc-sana-2026-08-28/
Deutsche Bank AG Buys New Stake in Sana Biotechnology, Inc. $SANA
August 28 at 3:37 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-buys-new-stake-in-sana-biotechnology-inc-sana-2026-08-28/
As U.S.-China biotech race heats up, Seattle makes its case to D.C.
August 27 at 12:58 AM  |  msn.comhttps://www.msn.com/en-us/news/other/as-us-china-biotech-race-heats-up-seattle-makes-its-case-to-dc/ar-AA2b4klV
As US.-China biotech race heats up, Seattle makes its case to DC
August 27 at 7:57 PM  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/as-us-china-biotech-race-heats-up-seattle-makes-its-case-to-dc/ar-AA2b4klV
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 5.7% Following Analyst Upgrade
August 27 at 1:51 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30985352
Sana Biotechnology (NASDAQ:SANA) Upgraded at TD Cowen
August 27 at 1:18 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30985159
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by Analysts
August 26 at 3:18 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30984015
Sana Biotechnology (NASDAQ:SANA) Shares Up 5.7% After Analyst Upgrade
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-shares-up-57-after-analyst-upgrade-2026-08-25/
Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by TD Cowen
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-sana-biotechnology-nasdaq-sana-stock-rating-upgraded-by-td-cowen-2026-08-25/
Bank of America Corp DE Has $8.49 Million Stock Position in Sana Biotechnology, Inc. $SANA
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-849-million-stock-position-in-sana-biotechnology-inc-sana-2026-08-25/
Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention
August 21, 2026  |  kalkinemedia.comK
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sana-biotechnology-inc-nasdaqsana-given-average-rating-of-moderate-buy-by-analysts-2026-08-21/
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2% - Time to Sell?
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sana-biotechnology-nasdaqsana-stock-price-down-62-time-to-sell-2026-08-20/
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9% - Still a Buy?
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sana-biotechnology-nasdaqsana-stock-price-up-89-still-a-buy-2026-08-19/
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)
August 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SANA/pressreleases/3906219/analysts-offer-insights-on-healthcare-companies-fortrea-holdings-inc-ftre-agomab-therapeutics-nv-adr-agmb-and-sana-biotechnology-sana/
Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-alphabet-inc-makes-new-982-million-investment-in-sana-biotechnology-inc-sana-2026-08-18/
Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter?
August 15, 2026  |  kalkinemedia.comK
Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/bank-of-america-issues-pessimistic-forecast-for-sana-biotechnology-nasdaqsana-stock-price-2026-08-14/
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% - Should You Sell?
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sana-biotechnology-nasdaqsana-shares-down-53-should-you-sell-2026-08-14/
HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-pessimistic-outlook-of-sana-q3-earnings-2026-08-13/
Analysts Are Bullish on Top Healthcare Stocks: Sana Biotechnology (SANA), Jade Biosciences (JBIO)
August 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ANIP-Q/pressreleases/3799166/analysts-are-bullish-on-top-healthcare-stocks-sana-biotechnology-sana-jade-biosciences-jbio/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$34.74 -2.44 (-6.56%)
As of 08/28/2026 04:00 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Celcuity stock logo

Celcuity NASDAQ:CELC

$88.44 -4.80 (-5.15%)
As of 08/28/2026 04:00 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$57.86 -2.64 (-4.36%)
As of 08/28/2026 04:00 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Sana Biotechnology stock logo

Sana Biotechnology NASDAQ:SANA

$3.93 -0.16 (-3.91%)
As of 08/28/2026 04:00 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas